ArticleJournal of vascular surgery. Venous and lymphatic disorders2026
Development and internal validation of a new Varicose Vein Recurrence Score for open superficial venous surgery.
Article in Journal of vascular surgery. Venous and lymphatic disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRecurrence after open superficial venous surgery occurs in 20% to 60% of patients at 5 years, yet no validated composite preoperative scoring system exists to quantify individual risk. We aimed to develop and internally validate a predictive model and a derived clinical risk score-the Varicose Vein Recurrence (VVR) Score-for 5-year recurrence after open surgery of the superficial venous system.
methodsThis retrospective single-center cohort study included consecutive patients undergoing saphenofemoral or saphenopopliteal junction ligation with or without trunk stripping and concomitant phlebectomies between January 2006 and December 2025. The primary outcome was duplex-confirmed recurrent reflux with clinically visible recurrent varices at 5 years; reintervention (open, endovenous, or foam) within 5 years served as a prespecified harder secondary end point. The primary analysis was conducted on extremities with complete 5-year outcome ascertainment. We used multivariable logistic regression with cluster-robust standard errors (patient-level clustering) for model development and cluster bootstrap resampling (500 replications) for internal validation. A simplified integer-based score was derived from shrinkage-adjusted coefficients. Prespecified sensitivity analyses included procedure-stratified subgroup models (three mutually exclusive primary subgroups-high ligation + stripping, high ligation alone, and phlebectomy alone-plus an overlapping saphenopopliteal junction-procedure subgroup), continuous calendar-year analyses with time × predictor interactions, treatment choice as a model covariate, inverse probability of censoring weighting, and Cox regression. Reporting followed the Transparent Reporting of a Multivariable Prediction Model for Individual Prognosis or Diagnosis guidelines (type 1b).
resultsAmong 12,480 eligible extremities (9210 patients), 10,142 (81.3%) had complete 5-year ascertainment and constituted the primary cohort. The 5-year recurrence rate was 25.1% (2546/10,142); 74.1% of recurrent extremities underwent reintervention (5-year reintervention rate, 18.6%). Six preoperative predictors were retained: anterior saphenous vein (formerly anterior accessory saphenous vein) reflux (odds ratio [OR], 2.33; 95% confidence interval [CI], 2.03-2.67), incompetent perforators (OR, 2.04; 95% CI, 1.77-2.35), body mass index of ≥30 kg/m
conclusionsThe VVR Score provides an internally validated tool for estimating 5-year recurrence risk after open superficial venous surgery using six preoperative clinical and duplex parameters. Performance was preserved across operative subgroups and for the harder reintervention end point. Because the score is derived in an open-surgical population, external validation in geographically diverse open-surgical cohorts and rederivation/recalibration before use in endothermal, nonthermal, or foam-sclerotherapy populations are essential before broader clinical adoption.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.